Centogene WKN: A2PUCU ISIN: NL0014040206 Kürzel: CNTG Forum: Aktien Thema: Hauptdiskussion

Hoffentlich ist es keine Fehlinvestition

Contact Us  Home Company 02/12/2020 CENTOGENE Biobank Receives Accreditation from College of American Pathologists State-of-the-art Biorepository in Rostock, Germany is the first CAP-accredited repository outside the U.S. Cambridge, MA, USA & Rostock, Germany February 12, 2020 – (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that its biorepository in Rostock, Germany, which they believe holds the largest diversity of positive tested cases in the field of inherited rare diseases, has received accreditation from the College of American Pathologists (CAP). The CAP’s Biorepository Accreditation Program is designed to improve the quality and consistency of biorepositories through requirements for standardization that will result in high-quality human specimens and genetic materials that can be used to support research. “CENTOGENE is proud to be the first biorepository to receive this accreditation from the CAP outside of the U.S., which recognizes our continued commitment to the highest quality standards, our pharmaceutical and scientific collaboration partners,” said Ellen Karges, VP Regulatory Compliance & Quality Management. “CENTOGENE reached another milestone by successfully completing their Biorepository Accreditation in partnership with CAP (College of American Pathologists). As the first Biorepository to receive this accreditation from CAP within Europe, we provide further proof of our commitment to the highest quality for our patients, pharmaceutical and scientific collaboration partners. Furthermore, CENTOGENE maintains the ethical handling of samples for the developing of diagnostic tools and supporting the development of new treatments that will have a positive impact on patients with rare diseases.” About CAP CAP is the world’s largest organization of board-certified pathologists and the leading provider of laboratory accreditation and proficiency testing programs. CAP, the first in the industry to offer an accreditation program for biorepositories, based the program on the principles of its Laboratory Accreditation Program. The accreditation process, a three-year accreditation cycle, includes on-site inspection, desk review, and optional education modules and gap assessment – designed to ensure the highest standard of patient care and application of best practice. For more information on CAP, please visit the following website: https://www.cap.org/

Hallo, was macht das unternehmen interessant? LG

Bin seit Dezember dabei und habe zwischendurch nachgelegt. Finde das Unternehmen interessant und sehe auf lange Sicht viel Potential. Viel Glück allen investierten 🍀

Lieber centogene oder doch biontech?

Ja den kenne ich. Kann es nicht deuten. Seit dem keine News mehr

Könnte was mit dem neuen Herausgeber der Berliner Zeitung, dessen Stasi-Vergangenheit und der von ihm angestoßenen positiven Berichterstattung in der Berliner Zeitung zu Centogene zu tun haben, wo er 3,27 % der Anteile halte. Hier ein 3 Wochen alter Artikel zum Thema aus eben jener Berliner Zeitung: https://www.berliner-zeitung.de/politik-gesellschaft/centogene-und-die-berliner-zeitung-li.1553

Keine ahnung

Was ist denn nur los mit der Aktie? Irgendjemand ne Vermutung wie es weiter geht? 😭😭😭

Kommt hier hoffentlich auch noch 🙈

Bin auch bei Biontech investiert. Geht die letzten Tage Richtung Norden.

Bin jetzt dabei. Viel Erfolg allen investierten

Ich guck mal was 15:30 passiert und bin dann evtl. dabei

Mal schauen wo es hingeht , warte mal noch auf gute Einstiegskurse

👍